ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Study summary

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Ask AI to explain this study

Start here

Key things to know

Main goalOther

This describes the study’s primary purpose.

What is being studiedChatBot

The study team can explain what participation involves.

Who it may be forLung Cancer · Gastrointestinal Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 1, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Abramson Cancer Center at Penn Medicine

Study sponsor

Study overview

What this study is about

Purpose: Other
Study type: Interventional
Phase: Phase 2
Sponsor: Abramson Cancer Center at Penn Medicine
Interventions being studied: Device: ChatBot

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Adults (age \>18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
Ability read and respond in English
Ability to provide informed consent to participate in the study

Reasons someone may not be able to joinExclusion criteria

Patients who are bed bound at baseline (ECOG 4)
Patients who rely on a wheelchair for ambulation

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 1, 2026. Always confirm current availability with the study team.

View original record ↗